Danish drug maker Santaris considers U.S. listing: investor

By Teis Jensen and Ole Mikkelsen COPENHAGEN (Reuters) - Danish venture capital firm Sunstone is considering whether to list its partly owned biotech company Santaris Pharma in the United States, and will probably make a decision this year, Sunstone told Reuters on Wednesday. Santaris, which was founded through a merger of two companies in 2003, develops drugs against liver cancer, head and neck cancer, and against metabolic and infectious diseases. In 2006, Sunstone was the lead investor in a 45 million euro venture investment in Santaris and is now the main owner with a 24.8 percent stake, around twice as much as the next two owners, pension fund LD and industrial foundation Novo A/S. Claus Andersson, partner in Sunstone and deputy chairman of Santaris' board, said that an initial public offering (IPO) has not been decided, but that it is one of the options considered. "If we are going to launch an IPO we would probably have to take the decision this year," Andersson said.



via Health News Headlines - Yahoo News http://ift.tt/1fjiQHs